{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Connective+Tissue+Disorders", "query": { "condition": "Connective Tissue Disorders" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16229, "total_pages": 1623, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Connective+Tissue+Disorders&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T12:47:28.286Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00497809", "title": "Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Neutropenia" ], "interventions": [ { "name": "AVI-014 versus Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AviGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 189, "start_date": "2007-08", "completion_date": "2009-07", "has_results": false, "last_update_posted_date": "2011-05-03", "last_synced_at": "2026-06-10T12:47:28.286Z", "location_count": 14, "location_summary": "Anaheim, California • Greenbrae, California • Los Angeles, California + 11 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "West Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00497809" }, { "nct_id": "NCT02370693", "title": "Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Diseases, Interstitial", "Systemic Sclerosis", "Scleroderma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2016-03", "completion_date": "2020-01-01", "has_results": true, "last_update_posted_date": "2021-08-25", "last_synced_at": "2026-06-10T12:47:28.286Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02370693" }, { "nct_id": "NCT00000414", "title": "Patient Education in Rheumatoid Arthritis and Osteoarthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Rheumatoid Arthritis", "Osteoarthritis" ], "interventions": [ { "name": "Arthritis Self-Management Program", "type": "BEHAVIORAL" }, { "name": "SMART Program", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1200, "start_date": "1996-07", "completion_date": "2001-04", "has_results": false, "last_update_posted_date": "2013-06-21", "last_synced_at": "2026-06-10T12:47:28.286Z", "location_count": 4, "location_summary": "Palo Alto, California • Wichita, Kansas • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000414" }, { "nct_id": "NCT03761914", "title": "Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Ovarian Cancer", "Colorectal Cancer", "Triple-negative Breast Cancer", "Small-cell Lung Cancer" ], "interventions": [ { "name": "galinpepimut-S", "type": "BIOLOGICAL" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Montanide", "type": "OTHER" }, { "name": "GM-CSF", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Sellas Life Sciences Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2019-09-30", "completion_date": "2022-10-27", "has_results": true, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-06-10T12:47:28.286Z", "location_count": 12, "location_summary": "Santa Rosa, California • Whittier, California • Miami, Florida + 9 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03761914" }, { "nct_id": "NCT05945784", "title": "Exploring Accessible Beauty for Individuals With Upper Extremity Deficits", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Stroke, Ischemic", "Stroke Hemorrhagic", "Stroke (CVA) or TIA", "Stroke, Acute", "Traumatic Brain Injury", "SCI - Spinal Cord Injury", "Ehlers-Danlos Syndromes (EDS)", "Lupus Erythematosus", "Guillain-Barre Syndrome", "Multiple Sclerosis", "Myasthenia Gravis", "Amyotrophic Lateral Sclerosis", "Graves Disease", "Muscular Dystrophies" ], "interventions": [ { "name": "Use of Rare Beauty makeup products", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Casa Colina Hospital and Centers for Healthcare", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 57, "start_date": "2023-07-21", "completion_date": "2023-09-29", "has_results": false, "last_update_posted_date": "2023-12-06", "last_synced_at": "2026-06-10T12:47:28.286Z", "location_count": 1, "location_summary": "Pomona, California", "locations": [ { "city": "Pomona", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05945784" }, { "nct_id": "NCT00829049", "title": "Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acne Vulgaris" ], "interventions": [ { "name": "Tazarotene Cream 0.1%", "type": "DRUG" }, { "name": "Adapalene", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 165, "start_date": "2007-10", "completion_date": "2008-10", "has_results": true, "last_update_posted_date": "2012-09-12", "last_synced_at": "2026-06-10T12:47:28.286Z", "location_count": 1, "location_summary": "Fremont, California", "locations": [ { "city": "Fremont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00829049" }, { "nct_id": "NCT00848055", "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "AbGn168 intravenous infusion", "type": "DRUG" }, { "name": "AbGn168 subcutaneous injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2008-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-11-01", "last_synced_at": "2026-06-10T12:47:28.286Z", "location_count": 6, "location_summary": "Boise, Idaho • Evansville, Indiana • Baltimore, Maryland + 3 more", "locations": [ { "city": "Boise", "state": "Idaho" }, { "city": "Evansville", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00848055" }, { "nct_id": "NCT02838628", "title": "Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Actinic Keratosis" ], "interventions": [ { "name": "50 mg of KX2-391 Ointment 1%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Almirall, S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2016-04-11", "completion_date": "2017-12-22", "has_results": true, "last_update_posted_date": "2021-04-14", "last_synced_at": "2026-06-10T12:47:28.286Z", "location_count": 16, "location_summary": "Fremont, California • La Mesa, California • Palm Springs, California + 12 more", "locations": [ { "city": "Fremont", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Coral Gables", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02838628" }, { "nct_id": "NCT00510367", "title": "Primary Breast Cancer Occurring Concomitant With Pregnancy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Cancer", "Pregnancy" ], "interventions": [ { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 61, "start_date": "2001-08-07", "completion_date": "2020-07-08", "has_results": false, "last_update_posted_date": "2020-07-10", "last_synced_at": "2026-06-10T12:47:28.286Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00510367" }, { "nct_id": "NCT03312907", "title": "A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Belimumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Rituximab-placebo", "type": "DRUG" }, { "name": "Standard therapy (Including Immunosuppressants)", "type": "DRUG" }, { "name": "Standard therapy (Excluding Immunosuppressants)", "type": "DRUG" }, { "name": "Steroid Taper", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 292, "start_date": "2018-03-01", "completion_date": "2021-07-07", "has_results": true, "last_update_posted_date": "2025-02-18", "last_synced_at": "2026-06-10T12:47:28.286Z", "location_count": 28, "location_summary": "Birmingham, Alabama • La Mesa, California • San Leandro, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Mesa", "state": "California" }, { "city": "San Leandro", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03312907" } ] }